Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlia CibichLPLeanne Purins

Discussion

Loading...

Member takes

Overview

Observational analysis shows enhanced survival in hematopoietic cell transplantation, suggesting benefits of donor lymphocyte infusion for myeloproliferative neoplasms.

Key Points

  • Survival improved significantly with advances in transplantation techniques and reduced non-relapse mortality over 35 years.
  • Overall survival rose from 40.5% to 58% between two decades, due to better donor and recipient matching.
  • Retrospective analysis of outcomes assesses transplant results and chimerism priorities across 864 patients since 1990.
  • Although relapse persists as the main barrier, donor lymphocyte infusion may improve outcomes for select myeloproliferative neoplasm patients.

Cite This Study

Cibich et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e531https://doi.org/10.1182/blood-2025-2508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved survival after post-transplant relapse of adult t-cell leukemia-lymphoma and trends of salvage therapy2025
  2. 2Results of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia2025
  3. 3Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies2025
  4. 4Treatment Strategies of Acute Myeloid Leukemia Relapses after Allogeneic Stem Cell Transplantation: Evidence from the GITMO Nationwide Italian Registry2025 · 1 citations
  5. 5Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP2025